Exploiting the mTOR paradox for disease prevention

Oncotarget

Volumn 3, Issue 10, 2012, Pages 1061-1063

  Iglesias Bartolome, Ramiro ^a   Silvio Gutkind, J ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL CYCLE ARREST; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; INHIBITION KINETICS; MOLECULAR MODEL; MOUTH CANCER; NONHUMAN; OXIDATIVE STRESS; SENESCENCE; TRANSLATION INITIATION;

EID: 84870692721     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.712     Document Type: Editorial

References (11)

1. Laplante M and Sabatini David M. Cell. 2012; 149:274-293.
2. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA and Gutkind JS. Cancer Prev Res (Phila). 2009; 2: 27-36.
3. Wander SA, Hennessy BT and Slingerland JM. J Clin Invest. 2011; 121(4): 1231-1241.
4. Castilho RM, Squarize CH, Chodosh LA, Williams BO and Gutkind JS. Cell Stem Cell. 2009; 5:279-289.
5. Iglesias-Bartolome R, Patel V, Cotrim A et al. Cell Stem Cell. 2012; 11: 401-414.
6. Yilmaz Odie;H, Valdez R, Theisen BK et al. Nature. 2006; 441: 475-482.
7. Demidenko ZN, Zubova SG, Bukreeva EI et al. Cell Cycle. 2009; 8: 1888-1895.
8. Blagosklonny MV. Aging. 2012; 4: 159-165.
9. Iglesias-Bartolome R and Gutkind JS. Curr Opin Cell Biol. 2011; 23: 716-723.
10. Begg AC, Stewart FA and Vens C. Nat Rev Cancer. 2011; 11(4):239-253.
11. Nonzee NJ, Dandade NA, Patel U et al. Cancer. 2008; 113: 1446-1452.